Authors : Dr. Muchukota Sushma; Bharathi Bhogenahalli Venkatappa; Gowthami V.; Nigel Viju Thomas; Souman Samanta

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/4wncwazy

Scribd : https://tinyurl.com/2w78ps4s

DOI : https://doi.org/10.38124/ijisrt/25aug886

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : The discovery of genomics has redefined oncology into precision rather than standardized treatment. But therapeutic resistance of either kind, intrinsic or acquired, is a serious impediment to sustained success. The present review outlines the domains on the crossroad between genomic intelligence and resistance evolution, where multi-omics profiling, high-throughput sequencing, and AI-based analytics are explaining the challenging complexity of the tumor and predicting resistance pathways. We review the contribution of clonal evolution, tumor plasticity and adaptive signaling in resistance to therapy, and we promote moving towards active molecular monitoring rather than snapshot ting genome. To preempt and target therapeutic escape we suggest a framework of adaptive precision oncology that comprehends real-time biomarkers, liquid biopsy follow-up and resistance-predictive algorithms. New approaches like combination therapy, recalibration of treatment with the help of AI, and longitudinal monitoring of genomes are mentioned. We also deal with moral and logistical obstacles of adopting these strategies, and especially in low-resource environments. The new era of precision oncology We now find ourselves in the next era of precision oncology that aims to personalization extend to real-time responsiveness, so that cancer treatment can increasingly be more adaptable, more resilient and more durable, achieved through personalizing the rapidly changing tumor biology with real-time dynamically changing genomic insights.

Keywords : Precision Oncology, Genomic Intelligence, Therapeutic Resistance, Adaptive Therapy, Liquid Biopsy, Tumor Heterogeneity.

References :

1. Ottaiano A, Ianniello M, Santorsola M, Ruggiero R, Sirica R, Sabbatino F, Perri F, Cascella M, Di Marzo M, Berretta M, Caraglia M. From chaos to opportunity: decoding cancer heterogeneity for enhanced treatment strategies. Biology. 2023 Aug 29;12(9):1183.
2. Liang YH. Pan-Cancer Universal Targets for Immunotherapy Resulted From Transposable Elements Activation (Doctoral dissertation, Washington University in St. Louis).
3. Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ. Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives. Hematology Reports. 2025 Mar 28;17(2):18.
4. Chambial P, Bhukya PL, Bahl V, Thakur N. Conventional methods of cancer therapy. InNanoparticles in Cancer Theranostics 2024 Oct 7 (pp. 173-195). CRC Press.
5. Mani DR, Krug K, Zhang B, Satpathy S, Clauser KR, Ding L, Ellis M, Gillette MA, Carr SA. Cancer proteogenomics: current impact and future prospects. Nature Reviews Cancer. 2022 May;22(5):298-313.
6. Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nature Reviews Cancer. 2020 Dec;20(12):743-56.
7. Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer and Metastasis Reviews. 2024 Mar;43(1):197-228.
8. Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020 Jan 14;12(1):8.
9. Adekola P. Multi-Scale Modeling in Cancer Systems Biology: Linking Transcriptomic Landscapes to Clinical Decision-Making.
10. Ali H. Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions. Int J Sci Res Arch. 2023;8(1):1012-30.
11. Raval H, Bhattacharya S. Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy. Current Cancer Drug Targets. 2025 Jun;25(6):586-619.
12. Mao Y, Shangguan D, Huang Q, Xiao L, Cao D, Zhou H, Wang YK. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. Molecular Cancer. 2025 Apr 23;24(1):123.
13. Soragni A, Knudsen ES, O’Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW. Acquired resistance in cancer: towards targeted therapeutic strategies. Nature Reviews Cancer. 2025 Jun 3:1-21.
14. Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nature reviews Drug discovery. 2020 Jan;19(1):39-56.
15. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. Journal of hematology & oncology. 2022 Sep 12;15(1):131.
16. Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix‐Panabières C, Staaf J, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J. Precision cancer medicine: Concepts, current practice, and future developments. Journal of internal medicine. 2023 Oct;294(4):455-81.
17. Athanasopoulou K, Michalopoulou VI, Scorilas A, Adamopoulos PG. Integrating Artificial Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions. Current Issues in Molecular Biology. 2025 Jun 19;47(6):470.
18. Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita N, McLaren K, Starkey M, Ward S, Wilding J, Ahmed M, Argasinska J. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic acids research. 2024 Jan 5;52(D1):D1210-7.
19. Nussinov R, Jang H, Tsai CJ, Cheng F. Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS computational biology. 2019 Mar 28;15(3):e1006658.
20. Abdi G, Tarighat MA, Jain M, Tendulkar R, Tendulkar M, Barwant M. Revolutionizing genomics: exploring the potential of next-generation sequencing. InAdvances in Bioinformatics 2024 Feb 6 (pp. 1-33). Singapore: Springer Nature Singapore.
21. Srivastava U, Kanchan S, Kesheri M, Gupta MK, Singh S. Types of omics data: genomics, metagenomics, epigenomics, transcriptomics, proteomics, metabolomics, and phenomics. InIntegrative Omics 2024 Jan 1 (pp. 13-34). Academic Press.
22. Paulson D, Johnson A. Integrating Artificial Intelligence with Genomic and Biomarker Data for the Advancement of Personalized Therapeutics in a Human-Centric Framework.
23. Nass SJ, Patlak M, Zevon E, editors. Improving cancer diagnosis and care: clinical application of computational methods in precision oncology: proceedings of a workshop.
24. Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards—current and future considerations for precision oncology. Nature Reviews Clinical Oncology. 2023 Dec;20(12):843-63.
25. Gupta S, Kumar D, Negi R, Singh R, Ansari MJ, Kashyap S, Mehrotra S, editors. Genomic intelligence: metagenomics and artificial intelligence. CRC Press; 2024 Dec 6.
26. Craig M, Jenner AL, Namgung B, Lee LP, Goldman A. Engineering in medicine to address the challenge of cancer drug resistance: from micro-and nanotechnologies to computational and mathematical modeling. Chemical Reviews. 2020 Nov 5;121(6):3352-89.
27. Chaux A. Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons.
28. Stubbs NM, Roady TJ, Schwermann MP, Eteshola EO, MacDonald WJ, Purcell C, Ryspayeva D, Verovkina N, Tajiknia V, Ghandali M, Voong V. Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resistance. 2025 Jun 5;8:27.
29. Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in immunology. 2021 May 27;12:656364.
30. Zhang Y, Wang W. Advances in tumor subclone formation and mechanisms of growth and invasion. Journal of Translational Medicine. 2025 Apr 21;23(1):461.
31. Huang Y. Towards New Approaches for Studying Personalized Gut Microbiota and Host-Microbe Interactions. Columbia University; 2022.
32. Terry S, Savagner P, Ortiz‐Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Molecular oncology. 2017 Jul;11(7):824-46.
33. Adhit KK, Wanjari A, Menon S. Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023 Dec 8;15(12).
34. Wang Z, Bai J, Jiang D, Li Y, Hu X, Efetov S, Cao Y, Kayaalp C, Dulskas A, Shaw D, Yang M. Liquid biopsy for monitoring minimal residual disease in colorectal cancer: a promising approach with clinical implications. Clinical Surgical Oncology. 2024 Sep 1;3(3):100056.
35. Chaux A. Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons.
36. Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Molecular Cancer. 2025 Jun 2;24(1):159.
37. Fu SW, Tang C, Tan X, Srivastava S. Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma. Expert review of molecular diagnostics. 2024 Oct 2;24(10):937-55.
38. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022 Jun 15;39(8):120.
39. Soragni A, Knudsen ES, O’Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW. Acquired resistance in cancer: towards targeted therapeutic strategies. Nature Reviews Cancer. 2025 Jun 3:1-21.
40. Rituraj, Pal RS, Wahlang J, Pal Y, Chaitanya MV, Saxena S. Precision oncology: transforming cancer care through personalized medicine. Medical Oncology. 2025 Jun 9;42(7):246.
41. Bhamidipaty V, Bhamidipaty DL, Bhamidipaty KD, Botchu R. Intelligent health care: applications of artificial intelligence and machine learning in computational medicine. InBlockchain and Digital Twin for Smart Hospitals 2025 Jan 1 (pp. 133-169). Elsevier.
42. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates. 2007 Jun 1;10(3):81-100.
43. Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: Mechanism, vulnerability and perspective implication for clinical treatment. Molecular Cancer. 2025 May 24;24(1):150.
44. Ravi R, Kesari HV. Novel study designs in precision medicine–basket, umbrella and platform trials. Current Reviews in Clinical and Experimental Pharmacology Formerly Current Clinical Pharmacology. 2022 Jul 1;17(2):114-21.
45. Cheng H. 2021 Prostate Cancer Clinical Consortium Clinical Research Site: University of Washington.
46. Freeman JW. Structural biology of the tumor microenvironment. InTumor Microenvironment: Cellular, Metabolic and Immunologic Interactions 2021 Dec 10 (pp. 91-100). Cham: Springer International Publishing.
47. Massa C, Wang Y, Marr N, Seliger B. Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway. International journal of molecular sciences. 2023 Apr 4;24(7):6736.
48. Janeeh AS, Bajbouj K, Rah B, Abu-Gharbieh E, Hamad M. Interplay between tumor cells and immune cells of the colorectal cancer tumor microenvironment: Wnt/β-catenin pathway. Frontiers in Immunology. 2025 Jun 18;16:1587950.
49. Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal transduction and targeted therapy. 2020 Oct 30;5(1):249.
50. Delahaye C, Figarol S, Pradines A, Favre G, Mazieres J, Calvayrac O. Early steps of resistance to targeted therapies in non-small-cell lung cancer. Cancers. 2022 May 25;14(11):2613.
51. Blanco-Heredia J, Souza CA, Trincado JL, Gonzalez-Cao M, Gonçalves-Ribeiro S, Gil SR, Pravdyvets D, Cedeño S, Callari M, Marra A, Gazzo AM. Converging and evolving immuno-genomic routes toward immune escape in breast cancer. Nature communications. 2024 Feb 21;15(1):1302.
52. Hesser LA. The Development of a Synbiotic Butyrate-Producing Bacterial Therapeutic for Food Allergy (Doctoral dissertation, The University of Chicago).
53. Sánchez-Bayona R, Catalán C, Cobos MA, Bergamino M. Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications. Cancers. 2025 Mar 7;17(6):913.
54. Narendra G, Choudhary S, Raju B, Verma H, Silakari O. Role of genetic polymorphisms in drug-metabolizing enzyme-mediated toxicity and pharmacokinetic resistance to anti-cancer agents: a review on the pharmacogenomics aspect. Clinical Pharmacokinetics. 2022 Nov;61(11):1495-517.
55. Singh JP, Gaur V, Dubey P. Precision, Prediction and Progress: A New Era in Pharmacology. International Journal of Innovative Science and Research Technology. 2025 Apr 22;10(4):888-910.
56. Ji J, Wang C, Fakih M. Rechallenge with BRAF and anti-EGFR inhibitors in patients with metastatic colorectal cancer harboring BRAFV600E mutation who progressed on cetuximab and encorafenib with or without binimetinib: a case series. Clinical Colorectal Cancer. 2022 Sep 1;21(3):267-71.
57. Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use. Cancers. 2022 May 26;14(11):2640.
58. Gatenby RA, Brown JS. The evolution and ecology of resistance in cancer therapy. Cold Spring Harbor perspectives in medicine. 2020 Nov 1;10(11):a040972.
59. Desai A, Vázquez TA, Arce KM, Corassa M, Mack PC, Gray JE, Pellini B. ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer. Cancers. 2024 Feb 26;16(5):940.
60. Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. NPJ Breast Cancer. 2024 Jun 19;10(1):50.
61. Mezei T, Kolcsár M, Joó A, Gurzu S. Image analysis in histopathology and cytopathology: from early days to current perspectives. Journal of Imaging. 2024 Oct 14;10(10):252.
62. Suura SR. Integrating Artificial Intelligence, Machine Learning, and Big Data with Genetic Testing and Genomic Medicine to Enable Earlier, Personalized Health Interventions. Deep Science Publishing; 2025 Apr 13.
63. Ross E. Inferring tumour evolution from single-cell and multi-sample data (Doctoral dissertation).
64. Romano C, Di Benedetto MD, Borri A. Stackelberg Evolutionary Games With Modulated Leadership: A Three-Agent Framework for Tumor-Immune Dynamics. IEEE Control Systems Letters. 2025 May 26.
65. Komi LS, Mustapha AY, Forkuo AY, Osamika D. Reviewing Pharmacovigilance Strategies Using Real-World Data for Drug Safety Monitoring and Management.
66. Du H, Wang J, Wang Z. Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. Frontiers in Oncology. 2025 Jun 18;15:1601808.
67. Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized medicine: recent progress in cancer therapy. Cancers. 2020 Apr 19;12(4):1009.
68. Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends in cancer. 2020 Sep 1;6(9):797-810.
69. El-Heliebi A. for the Analysis of Cell-Free Circulating DNA. Nucleic Acid Nanotheranostics: Biomedical Applications. 2019 Feb 26:133.
70. Pourmir I. Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy (Doctoral dissertation, Université Paris Cité).
71. Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduction and Targeted Therapy. 2020 Oct 19;5(1):241.
72. Liu H. Angiotensin system inhibition in pancreatic ductal adenocarcinoma. Harvard University; 2017.
73. Zhao S, Zhu A, Mozannar H, Sontag D, Talwalkar A, Chen V. Codinggenie: A proactive llm-powered programming assistant. arXiv preprint arXiv:2503.14724. 2025 Mar 18.
74. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology. 2020 Jun 15;4(1):19.
75. Bronkhorst AJ, Holdenrieder S. The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization. Medizinische Genetik. 2023 Nov 29;35(4):201-35.